癌症（英文版）2012，Vol.31Issue(6)：287-294,8.DOI:10.5732/cjc.011.10376
Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy
Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy
摘要
Abstract
Establishing Epstein-Barr virus (EBV)-specific cytolytic T lymphocytes (EBV-CTLs) from peripheral blood mononuclear cells (PBMCs) for adoptive immunotherapy has been reported in EBV-associated malignancies including Hodgkin's lymphoma and nasopharyngeal carcinoma (NPC).In the current study,we performed ex vivo expansion of tumor-infiltrating lymphocytes (TILs) obtained from NPC biopsy specimens with a rapid expansion protocol using anti-CD3 monoclonal antibody (OKT3),recombinanthuman interleukin (IL)-2,and irradiated PBMCs from healthy donors to initiate the growth of TILs.Young TIL cultures comprised of more than 90％ of CD3+ T cells,a variable percentage of CD3+CD8+ and CD3+CD4+ T cells,and less than 10％ of CD3-CD16+ natural killer cells,a similar phenotype of EBV-CTL cultures from PBMCs.Interestingly,TIL cultures secreted high levels of the Th1 cytokines,interferon gamma (IFNγ) and tumor necrosis factor-alpha (TNF-α),and low levels of the Th2 cytokines,IL-4 and IL10.Moreover,young TILs could recognize autologous EBV-transformed B lymphoblast cell lines,but not autologous EBV-negative blast cells or allogeneic EBV-negative tumor cells.Taken together,these data suggest that ex vivo expansion of TILs from NPC biopsy tissue is an appealing alternative method to establish T cell-based immunotherapy for NPC.关键词
Tumor-infiltrating lymphocytes/immunotherapy/nasopharyngeal carcinomaKey words
Tumor-infiltrating lymphocytes/immunotherapy/nasopharyngeal carcinoma引用本文复制引用
Jia He,Xiao-Feng Tang,Qiu-Yan Chen,Hai-Qiang Mai,Zhou-Feng Huang,Jiang Li,Yi-Xin Zeng..Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy[J].癌症（英文版）,2012,31(6):287-294,8.基金项目
We thank members of Dr.Yi-Xin Zeng's team,Sun Yat-sen University Cancer Center, for helpful discussions.This work was supported by grants from the National Natural Science Foundation of China (No.224-30872981) and Guangdong Province NaturalScience Foundation (No.10151008901000156). （No.224-30872981）
